APG1252
APG1252 is a pharmaceutical drug with 7 clinical trials. Currently 3 active trials ongoing. Historical success rate of 33.3%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
25.0%
1 of 4 finished
75.0%
3 ended early
3
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Clinical Trials (7)
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
APG-1252 in Patients With SCLC or Advanced Solid Tumors
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7